AngioDynamics, Inc. (ANGO)
Price:
11.05 USD
( - -0.21 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Hologic, Inc.
VALUE SCORE:
6
2nd position
DENTSPLY SIRONA Inc.
VALUE SCORE:
9
The best
Pro-Dex, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
NEWS
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
zacks.com
2025-10-03 09:26:15AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
AngioDynamics: Discounted Sales Multiple With Real Growth Engines
seekingalpha.com
2025-10-02 15:00:57AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong performance from Auryon, AlphaVac, AngioVac, and NanoKnife products. Gross margin improved to 55.3%, operating costs are under control, and management expects positive cash flow and raised guidance for FY 2026.
Why Did AngioDynamics Stock Pop Today?
fool.com
2025-10-02 12:28:03AngioDynamics (ANGO 7.00%) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
seekingalpha.com
2025-10-02 10:02:08AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
benzinga.com
2025-10-02 09:44:00U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2025-10-02 08:11:04AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
businesswire.com
2025-10-02 06:00:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million.
Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings
benzinga.com
2025-10-01 09:57:57AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.
Wall Street Week Ahead
seekingalpha.com
2025-09-28 06:35:57Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com
2025-09-22 13:31:09ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
businesswire.com
2025-09-18 08:00:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Company's management will host a conference call at 8:00 am ET the same day to.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com
2025-08-21 14:31:12ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
seekingalpha.com
2025-08-17 08:23:18AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results confirm an inflection point: MedTech sales grew 19.5% in FY25, adjusted EBITDA turned positive, and the company now boasts a strong net cash balance sheet. Favorable sector trends, regulatory wins, and unique product positioning (Auryon, AlphaVac, NanoKnife) underpin robust growth prospects and expanding addressable markets.
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
businesswire.com
2025-08-06 16:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0.
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
businesswire.com
2025-07-28 08:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical.
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
businesswire.com
2025-07-23 08:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate.
No data to display
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
zacks.com
2025-10-03 09:26:15AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
AngioDynamics: Discounted Sales Multiple With Real Growth Engines
seekingalpha.com
2025-10-02 15:00:57AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong performance from Auryon, AlphaVac, AngioVac, and NanoKnife products. Gross margin improved to 55.3%, operating costs are under control, and management expects positive cash flow and raised guidance for FY 2026.
Why Did AngioDynamics Stock Pop Today?
fool.com
2025-10-02 12:28:03AngioDynamics (ANGO 7.00%) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
seekingalpha.com
2025-10-02 10:02:08AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
benzinga.com
2025-10-02 09:44:00U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2025-10-02 08:11:04AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
businesswire.com
2025-10-02 06:00:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million.
Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings
benzinga.com
2025-10-01 09:57:57AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.
Wall Street Week Ahead
seekingalpha.com
2025-09-28 06:35:57Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com
2025-09-22 13:31:09ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
businesswire.com
2025-09-18 08:00:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Company's management will host a conference call at 8:00 am ET the same day to.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com
2025-08-21 14:31:12ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
seekingalpha.com
2025-08-17 08:23:18AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results confirm an inflection point: MedTech sales grew 19.5% in FY25, adjusted EBITDA turned positive, and the company now boasts a strong net cash balance sheet. Favorable sector trends, regulatory wins, and unique product positioning (Auryon, AlphaVac, NanoKnife) underpin robust growth prospects and expanding addressable markets.
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
businesswire.com
2025-08-06 16:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0.
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
businesswire.com
2025-07-28 08:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical.
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
businesswire.com
2025-07-23 08:30:00LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate.